Solid biosciences announces $90 million private placement

Cambridge, mass., dec. 11, 2020 (globe newswire) -- solid biosciences inc. (nasdaq: sldb), a life sciences company focused on advancing meaningful therapies for duchenne muscular dystrophy (duchenne), today announced that it has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $90 million private placement, which is expected to close on or about december 15, 2020, subject to the satisfaction of customary closing conditions.
SLDB Ratings Summary
SLDB Quant Ranking